Insight

Archimed wraps up fifth fund at $3.75bn

The initial target was 2 billion euros.

-
  • The fund will invest in European and North American healthcare companies
  • MED Platform II began fundraising in January 2022
  • The fund’s limited partners include a wide range of institutional investors and family offices

Archimed has closed its fifth fund MED Platform II at $3.75 billion (3.5 billion euros). The initial target was 2 billion euros.

The fund will invest in European and North American healthcare companies.

MED Platform II began fundraising in January 2022.

The fund’s limited partners include a wide range of institutional investors and family offices.

“Like its predecessor, MED Platform II offers more than just financial backing,” says Archimed Chairman Denis Ribon in a statement. “Most of the Archimed team have medical, scientific or operational backgrounds so we fully appreciate the lofty ambitions of our partners, as well as the challenges they face.”

With offices in Europe, North America and Asia, Archimed is focused exclusively on healthcare industries. Archimed manages 8 billion euros across its various funds.